The enduring gap in educational attainment in schizophrenia according to the past 50 years of published research: a systematic review and meta-analysis
- PMID: 35717966
- DOI: 10.1016/S2215-0366(22)00121-3
The enduring gap in educational attainment in schizophrenia according to the past 50 years of published research: a systematic review and meta-analysis
Abstract
Background: Educational attainment is associated with wellbeing and health, but patients with schizophrenia achieve lower levels of education than people without. Several effective interventions can ameliorate this situation. However, the magnitude of the education gap in schizophrenia and its change over time are unclear. We aimed to reconstruct the trajectories of educational attainment in patients with schizophrenia and, if reported, their healthy comparator controls.
Methods: We did a systematic review and meta-analysis including all studies reporting on patients with schizophrenia (of mean age ≥18 years) and describing the number of years of education of the participants, with or without healthy controls. There were no other design constraints on studies. We excluded studies that included only patients with other schizophrenia spectrum disorders and studies that did not specify the number of years of education of the participants. 22 reviewers participated in retrieving data from a search in PubMed and PsycINFO (Jan 1, 1970, to Nov 24, 2020). We estimated the birth date of participants from their mean age and publication date, and meta-analysed these data using random-effects models, focusing on educational attainment, the education gap, and changes over time. The primary outcome was years of education. The protocol was registered on PROSPERO (CRD42020220546).
Findings: From 32 593 initial references, we included 3321 studies reporting on 318 632 patients alongside 138 675 healthy controls (170 941 women and 275 821 men from studies describing sex or gender; data on ethnicity were not collected). Patients' educational attainment increased over time, mirroring that of controls. However, patients with schizophrenia in high-income countries had 19 months less education than controls (-1·59 years, 95% CI -1·66 to -1·53; p<0·0001), which is equivalent to a Cohen's d of -0·56 (95% CI -0·58 to -0·54) and implies an odds ratio of 2·58 for not completing 12 years of education (ie, not completing secondary education) for patients compared with controls. This gap remained stable throughout the decades; the rate of change in number of total years of education in time was not significant (annual change: 0·0047 years, 95% CI -0·0005 to 0·0099; p=0·078). For patients in low-income and middle-income countries, the education gap was significantly smaller than in high-income countries (smaller by 0·72 years, 0·85 to 0·59; p<0·0001), yet there was evidence that this gap was widening over the years, approaching that of high-income countries (annual change: -0·024 years, -0·037 to -0·011; p=0·0002).
Interpretation: Patients with schizophrenia have faced persistent inequality in educational attainment in the last century, despite advances in psychosocial and pharmacological treatment. Reducing this gap should become a priority to improve their functional outcomes.
Funding: Ciencia y Tecnología para el Desarrollo (CYTED) to the Latin American Network for the Study of Early Psychosis (ANDES).
Copyright © 2022 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests NAC has received personal fees from Janssen, outside the submitted work. AG has been a consultant and/or advisor to or has received honoraria from Aché, Daiichi-Sankyo, Torrent, Bayer, Cristalia, Daiichi-Sankyo and Janssen. CA has been a consultant to or has received honoraria or grants from Acadia, Angelini, Biogen, Boehringer, Gedeon Richter, Janssen Cilag, Lundbeck, Minerva, Otsuka, Pfizer, Roche, Sage, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion, and Takeda. DMB has received consulting fees from Boehringer-Ingelheim. SE-L has received consulting fees from Janssen. CUC has been a consultant and/or advisor to or has received honoraria from AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Axsome, Damitsa, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Janssen/Johnson & Johnson, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Medscape, Merck, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Relmada, Rovi, Seqirus, Servier, SK Life Science, Sumitomo Dainippon, Sunovion, Supernus, Takeda, Teva, and Viatris. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck, Relmada, Rovi, and Teva. He has received grant support from Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of LB Pharma. All other authors declare no competing interests.
Comment in
-
Why is the educational attainment of people with schizophrenia lagging so far behind?Lancet Psychiatry. 2022 Jul;9(7):528-529. doi: 10.1016/S2215-0366(22)00190-0. Lancet Psychiatry. 2022. PMID: 35717952 No abstract available.
-
Schizophrenie ist ein Bildungschancen-Killer.MMW Fortschr Med. 2023 Apr;165(8):26. doi: 10.1007/s15006-023-2591-y. MMW Fortschr Med. 2023. PMID: 37081341 Review. German. No abstract available.
Similar articles
-
Educational and income inequalities across diseases in Denmark: a register-based cohort study.Lancet Public Health. 2024 Nov;9(11):e916-e924. doi: 10.1016/S2468-2667(24)00128-2. Epub 2024 Oct 5. Lancet Public Health. 2024. PMID: 39374604
-
Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.Med J Aust. 2020 Dec;213 Suppl 11:S3-S32.e1. doi: 10.5694/mja2.50881. Med J Aust. 2020. PMID: 33314144
-
[What support of young presenting a first psychotic episode, when schooling is being challenged?].Encephale. 2017 Dec;43(6):570-576. doi: 10.1016/j.encep.2017.10.001. Epub 2017 Nov 8. Encephale. 2017. PMID: 29128195 Review. French.
-
Increased educational attainment and its effect on child mortality in 175 countries between 1970 and 2009: a systematic analysis.Lancet. 2010 Sep 18;376(9745):959-74. doi: 10.1016/S0140-6736(10)61257-3. Lancet. 2010. PMID: 20851260
-
Temporal trends in associations between severe mental illness and risk of cardiovascular disease: A systematic review and meta-analysis.PLoS Med. 2022 Apr 19;19(4):e1003960. doi: 10.1371/journal.pmed.1003960. eCollection 2022 Apr. PLoS Med. 2022. PMID: 35439243 Free PMC article.
Cited by
-
Reliability of clinical judgment for evaluation of informed consent in mental health settings and the validation of the Evaluation of Informed Consent to Treatment (EICT) scale.Front Psychol. 2024 Mar 19;15:1309909. doi: 10.3389/fpsyg.2024.1309909. eCollection 2024. Front Psychol. 2024. PMID: 38566948 Free PMC article.
-
Systemic inflammation and cortical neurochemistry in never-medicated first episode-psychosis individuals.Brain Behav Immun. 2023 Jul;111:270-276. doi: 10.1016/j.bbi.2023.05.001. Epub 2023 May 5. Brain Behav Immun. 2023. PMID: 37149107 Free PMC article.
-
Early intervention in eating disorders: introducing the chronopathogram.Eat Weight Disord. 2025 Jan 23;30(1):9. doi: 10.1007/s40519-025-01715-6. Eat Weight Disord. 2025. PMID: 39847276 Free PMC article. Review.
-
Comparing the World Psychiatric Association and European Psychiatric Association Codes of Ethics: Discrepancies and shared grounds.Eur Psychiatry. 2024 May 7;67(1):e38. doi: 10.1192/j.eurpsy.2024.1748. Eur Psychiatry. 2024. PMID: 38712570 Free PMC article.
-
The S20 Brazilian Mental Health Report for Building a Just World and a Sustainable Planet: Part II.Braz J Psychiatry. 2024;46:e20243707. doi: 10.47626/1516-4446-2024-3707. Epub 2024 Jun 14. Braz J Psychiatry. 2024. PMID: 38875470 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous